NM_001034853.2(RPGR):c.296C>T (p.Thr99Ile) is a missense variant predicted to substitute threonine with isoleucine at amino acid 99. This variant is absent from hemizygous individuals in gnomAD v4.1.0 (PM2_Supporting). At least one proband harboring this variant exhibits a phenotype including early onset (1 pt), a family history consistent with X-linked inheritance (2 pt), visual field constriction (0.5 pts), and rod involvement greater than cone (1 pt), which together are specific for RPGR-related retinopathy (4.5pts, PMID: 21857984, PP4). This variant has been reported in at least 2 additional apparently unrelated probands meeting the PS4 requirement of some functional vision impairment in affected males by age 30 years or decreased or absent cone and/or rod electroretinogram responses (PMID: 32702353, 31213501, 21857984, PS4_supporting). The variant has been reported to segregate with retinal dystrophy through at least 3 affected meioses from 1 family (PP1_moderate; PMID: 21857984). Another missense variant in the same codon, NM_001034853.2(RPGR):c.296C>A (p.Thr99Asn), (PMIDs: 32531858, 32702353, 10482958, and 28863407) has previously been classified as likely pathogenic for RPGR-related retinopathy by the ClinGen X-linked IRD VCEP, while no benign missense variants have been identified in this codon. The present variant has a higher Grantham’s distance (89) than the comparison variant (65), and SpliceAI has been used to confirm that neither variant has a predicted impact on RPGR splicing (PM5_Supporting). The computational predictor REVEL gives a score of 0.813, which is between the ClinGen X-linked IRD VCEP threshold of 0.773 to 0.931 and predicts a damaging effect on RPGR function (PP3_moderate). The computational splicing predictor SpliceAI gives a delta score of 0.03 for acceptor gain, which is below the ClinGen X-linked IRD VCEP threshold of >0.2 and does not predict that the variant disrupts RPGR splicing. In summary, this variant is classified as likely pathogenic for RPGR-related retinopathy based on the ClinGen X-linked Inherited Retinal Disease Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for RPGR Version 1.0.0; PM2_supporting, PM5_supporting, PP1_moderate, PP3_moderate, and PP4. (date of approval 05/16/2025).